5-Amino-1MQ
Taken for fat loss and metabolism
NNMT inhibitor, not a peptide
Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.
Small molecule, not a peptide
At a glance
Why people take it. And what backs it up.
-
Burn fat, boost metabolism
Animal studies only
Taken as capsules or shots, often stacked with weight-loss drugs, hoping to burn more fat and rev up metabolism.
Sources (4)
-
“5-Amino-1MQ is the one that keeps showing up in “biohacker fat-loss stack” conversations — and, unusually, it’s an oral capsule, not another injectable.”
-
“BPC/TB4 for the disc, 5-Amino-1MQ and SLUP oral. Hitting machines 4-5x a week, 1500cal/150g protein. Tryna get lean.”
-
ClinicAlpha Rejuvenation (men’s health clinic): “5-Amino-1MQ Dosage: Guide 2025” (opens in a new tab)
“5-Amino-1-methylquinolinium (5-Amino-1MQ) is a selective NNMT inhibitor that boosts NAD+ levels, enhancing mitochondrial function and fat oxidation.”
-
“Treatment of diet-induced obese mice systemically with a potent NNMT inhibitor significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma total cholesterol levels.”
-
Evidence briefing
Sources checkedWhat the sources support.
5-Amino-1MQ is an experimental NNMT-inhibitor small molecule, not a peptide or approved medicine. Weight/fat findings are from mouse research; no human clinical study was located.
Mouse studies do not establish human safety or efficacy; a clinical route has not been established.
The research. What’s been studied.
-
Animal & lab studies
Mouse body-weight findings
A short study in diet-induced obese mice reported lower body weight and fat mass after 5-amino-1MQ treatment.
-
Animal & lab studies
Fat-cell findings
Cell and mouse experiments reported changes in adipocyte size and fat metabolism; these do not establish effects in people.
-
Unverified
Human evidence
No human clinical study of 5-amino-1MQ was identified.
What do these labels mean?
- Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
- Early human studies: small, preliminary or limited human studies.
- Animal & lab studies: animal or laboratory findings that do not establish effects in people.
- Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (4)
Reported effects and evidence.
A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.
-
Preclinical mouse experiment
Review of “Fat loss”
In an 11-day obese-mouse experiment, 5-amino-1MQ reduced body weight and fat measures without reduced food intake.
Limitations and applicability. Small, short mouse proof-of-concept; nonpeptide small molecule. Not human weight-loss evidence.
Original collected claim and review history
Original title: Fat loss
Obese mice on a high-fat diet lost weight and fat mass without eating less.
Original label: animal. Preserved for traceability; the reviewed wording above qualifies this record.
Record 5-amino-1mq:benefit:1 · Annotated 2026-10-01 · Review method
-
Preclinical cells plus mice
Review of “Smaller fat cells”
Cell experiments reported increased NAD+; a separate obese-mouse experiment found smaller adipocytes.
Limitations and applicability. Cellular NAD+ and mouse adipocyte findings should be separated; “animal” obscures mixed model types.
Original collected claim and review history
Original title: Smaller fat cells
Shrank fat cells and raised NAD+ levels inside them.
Original label: animal. Preserved for traceability; the reviewed wording above qualifies this record.
Record 5-amino-1mq:benefit:2 · Annotated 2026-10-01 · Review method
-
Preclinical mouse experiment
Review of “Lower cholesterol”
The same obese-mouse experiment reported lower total plasma cholesterol.
Limitations and applicability. Same experiment, not independent confirmation or human cholesterol efficacy.
Original collected claim and review history
Original title: Lower cholesterol
Lowered total cholesterol in the same mouse study.
Original label: animal. Preserved for traceability; the reviewed wording above qualifies this record.
Record 5-amino-1mq:benefit:3 · Annotated 2026-10-01 · Review method
-
Preclinical aged-mouse injury experiment
Review of “Muscle recovery with age”
5-amino-1MQ improved muscle-stem-cell and regeneration measures after experimental injury in aged mice.
Limitations and applicability. Exact compound confirmed as 5-amino-1-methylquinolinium; findings concern chemically injured mouse muscle.
Original collected claim and review history
Original title: Muscle recovery with age
In old mice, blocking NNMT helped muscle stem cells repair injured muscle.
Original label: animal. Preserved for traceability; the reviewed wording above qualifies this record.
Record 5-amino-1mq:benefit:4 · Annotated 2026-10-01 · Review method
The research in detail
Evidence category
Mostly animal and cell studies
A 2017 study tested 5-amino-1MQ in cells and diet-induced obese mice. No human clinical studies were identified; results from mice do not establish human benefit or safety.
Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.
Risks and unknowns. What to know first.
Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.
- Human safety profile unknown.
What people report
-
Study
Evidence for weight or metabolic effects comes from mouse studies; one 2024 study in diet-induced obese mice found dose-dependent limits on weight and fat gain, but no human trial exists.
Published dosing records. No established dose.
Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.
5-Amino-1MQ has only been tested in cells and in mice and rats, mainly in obesity research. PubMed and ClinicalTrials.gov list no human study, and no regulator has approved it.
Any dose you see online for it is a guess, not a tested dose.
Community protocols. Reported online. Not clinically validated.
Community reports Collection date: 30 Sep 2026The most widely quoted protocol is oral: 50 mg a day to start, rising to 100–150 mg a day, often in cycles of about 8 weeks on and 4 weeks off.
More about this
Injection protocols disagree wildly: one clinic lists 150–500 mcg a day, while a protocol site treats a whole 50 mg vial as one daily dose, a roughly 100-fold to 1,000-fold gap.
Oral capsules
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Clinic: Alpha Rejuvenation clinic (J Broad MD): “5-Amino-1MQ Dosage”
- Review: MyPeptideMatch (protocol website): “5-Amino-1MQ Dosing Protocol: 50 mg Vial”
- Clinic: Alpha Rejuvenation clinic (cycles)
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 50 mg a day to start, then 100–150 mg a day
- How often
- Once or twice a day
- Route
- Oral
- How long
- About 8 weeks
- Cycle
- 8 weeks on, 4 weeks off (other variants: 6 on and 3 off, or 12 on and 6 off)
- Ramp
- Start at 50 mg; increase if tolerated
- 5-Amino-1MQ is a small molecule, not a peptide, and is usually sold as capsules.
Sources (3)
-
ClinicAlpha Rejuvenation clinic (J Broad MD): “5-Amino-1MQ Dosage” (opens in a new tab)
“Dosage for capsules is 50-100 mg daily, divided into 1-2 doses.”
-
ReviewMyPeptideMatch (protocol website): “5-Amino-1MQ Dosing Protocol: 50 mg Vial” (opens in a new tab)
“Start at 50 mg/day; advance to 100–150 mg/day if tolerated without side effects.”
-
ClinicAlpha Rejuvenation clinic (cycles) (opens in a new tab)
“8 weeks on/4 off (standard); 6 on/3 off (conservative); 12 on/6 off (extended).”
Injection, microgram doses (clinic)
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 150–500 mcg a day
- How often
- Once a day (500 mcg split into 250 mcg morning and evening)
- Route
- Injection under the skin
- Timing
- Morning, fasted
- How long
- 8–12 weeks
- Cycle
- 8 weeks on, 4 weeks off
- Ramp
- 150 mcg for weeks 1–2, 300 mcg for weeks 3–8, then 500 mcg
- Mixing
- 10 mg vial + 2 mL bacteriostatic water (5 mg/mL)
- This is about 100 to 1,000 times less than the oral doses above.
Sources (1)
-
ClinicAlpha Rejuvenation clinic (J Broad MD): “5-Amino-1MQ Dosage” (opens in a new tab)
“The recommended 5-Amino-1MQ dosage for subcutaneous (subQ) injection ranges from 150-500 mcg daily.”
Show all 3 protocolsShow fewer protocols
Injection, milligram doses from a 50 mg vial
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 50 mg (a whole vial) a day
- How often
- Once a day
- Route
- Injection under the skin (the same site says oral use is strongly preferred)
- Mixing
- 50 mg vial + 10 mL bacteriostatic water (5 mg/mL)
- Implies injecting 10 mL a day, which the site itself treats as impractical.
Sources (1)
-
ReviewMyPeptideMatch (protocol website) (opens in a new tab)
“50 mg starting dose; assess metabolic response (thermogenesis, energy) before advancing”
Where the numbers come from
No human studies were found. Published dosing data come from mouse studies of the NNMT inhibitor (for example obese mice dosed once a day for 28 days). The 50 mg capsule dose appears to be a vendor convention, and where the microgram injection dose came from is unclear.
Research notes
Major disagreement: the injectable dose ranges from 150 mcg to 50 mg a day depending on the source, and neither figure has a documented basis. The site’s vendor lists a 50 mg product, which would fit the milligram-dose reading if it is a vial. No regulator warning or user side-effect report specific to 5-Amino-1MQ was found; the Reddit archive could not be searched reliably for this item (rate limits).
What it is. In plain English.
An experimental NNMT-inhibitor small molecule studied in cells and mice; no human clinical evidence was identified.
A methylquinolinium compound studied as an inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme involved in cellular metabolism.
In cells and mice, NNMT inhibition has been proposed to affect NAD+ balance and energy use in fat cells. These findings have not been shown in people.
Reviewed 2026-10-01.
Structure. A computed model.
, not measured
No experimental structure of 5-Amino-1MQ is in the , alone or bound to its target enzyme, NNMT. This is a computed model of its cation, 5-amino-1-methylquinolinium: a shape calculated from its atoms and bonds. Carbon atoms are gray and nitrogen is blue; hydrogen atoms aren’t drawn. Its formula and bonds were checked against the molecule’s known structure.
PubChem CID 950107. Rendered with Mol* (Sehnal et al., 2021).
Specs. The facts at a glance.
- Type
- small molecule
- Sold as
- 5-Amino-1MQ (chloride) 50 mg
- Regulatory status
- Not approved. .
- Also known as
- NNMT inhibitor, not a peptide
Sources. What this page rests on.
Every source behind this page, with what it says and when it was checked, is in the Source library.
5-Amino-1MQ in the Source library
Original overview and research notes · annotated 2026-10-01
Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.
Fat-cell metabolism (NNMT blocker)
A small molecule that blocks an enzyme in fat cells, studied only in obese mice.
A methylquinolinium compound that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that’s overactive in fat tissue in obesity.
Blocking NNMT is thought to keep more NAD+ available and raise energy use inside fat cells, shrinking them.
In a 2018 study, obese mice on a high-fat diet lost weight and fat mass on it without eating less. No human trials have been published.
Original status record: Not approved. Research chemical.
More in Weight & metabolism.
- SemaglutideApproved weight-loss and diabetes drugFDA-approved
- TirzepatideApproved weight-loss, diabetes, sleep-apnea drugFDA-approved
- RetatrutideExperimental drug for major weight lossHuman trials
- CagrilintideExperimental appetite drug for weight lossHuman trials
- EloralintideExperimental appetite shot for weight lossHuman trials
- SurvodutideExperimental drug for weight lossHuman trials
- AOD-9604Taken to burn fatHuman trials
- MOTS-cTaken for metabolism and enduranceAnimal & lab only